Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL January 24, 2020 • 7:00 AM EST
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference January 23, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study December 16, 2019 • 3:15 PM EST
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL December 11, 2019 • 4:05 PM EST
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia December 10, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 3, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD November 26, 2019 • 4:05 PM EST
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference November 25, 2019 • 4:05 PM EST